Garcia-Manero, G
Sekeres, M A
Egyed, M
Breccia, M
Graux, C
Cavenagh, J D
Salman, H
Illes, A
Fenaux, P
DeAngelo, D J
Stauder, R
Yee, K
Zhu, N
Lee, J-H
Valcarcel, D http://orcid.org/0000-0002-8747-078X
MacWhannell, A
Borbenyi, Z
Gazi, L
Acharyya, S
Ide, S
Marker, M
Ottmann, O G
Article History
Received: 7 October 2016
Revised: 13 February 2017
Accepted: 23 February 2017
First Online: 26 May 2017
Competing interests
: GG-M, ME, JDC, HS, PF, NZ, J-HL, AM and ZB declare no conflict of interest; MAS has served on the board of directors/advisory committees for Celgene; MB has received honoraria from Novartis, BMS, Pfizer and Ariad; CG has received honoraria from and has served on the board of directors/advisory committees for Celgene, Novartis and Amgen; AI has served on the board of directors/advisory committees for Roche, Takeda and Janssen; DJD has held consulting and advisory roles with Ariad, BMS, Novartis, Pfizer, Incyte and Amgen; RS has received research funding and honoraria from Novartis, Celgene and Teva, has received honoraria from Hospira, and has served on the board of directors/advisory committees for Celgene; KY has served on the board of directors/advisory committees for Novartis and Celgene and has received research funding from Novartis, Celgene and Astex, and honoraria from Novartis; DV has received honoraria from and has served on the speaker's bureaus and board of directors/advisory committees for Celgene, Novartis, Amgen, Takeda and Pfizer, has held a consulting role with Celgene, has received honoraria from and served on the board of directors/advisory committees for Boehringer Ingelheim, and has received honoraria from and served on the speaker's bureau for Astellas; LG and SA are employees of Novartis; SI and MM are employees of and have equity ownership of Novartis; OGO has held a consulting role, has received research funding and honoraria from, and has served on the board of directors/advisory committees for Novartis.